Please amend the application as follows:

IN THE SPECIFICATION

Please cancel the Sequence Listing on pages 65-87 and replace it with the substitute Sequence Listing submitted herewith as Exhibit A beginning on the page following the Abstract. Please renumber original pages 88-94 accordingly.

IN THE CLAIMS

In accordance with amendment practice pursuant to Rule 1.121(c)(1)(i), please enter the "clean" set of "rewritten claims" as set forth below. A "marked up" version of the amended claims is attached hereto as Exhibit B pursuant to Rule 1.121(c)(1)(ii).

- 4. (Amended) An isolated nucleic acid molecule encoding a recombinant polypeptide comprising SEQ ID NO:5 or a polypeptide with at least 80% identity to SEQ ID NO:5, and having alcohol and aldehyde dehydrogenase (AADH) activity.
 - 5. (Amended) An isolated nucleic acid molecule of claim 4, wherein the nucleic acid molecule is selected from the group consisting of a linear DNA, a circular DNA and an insertion DNA fragment on a chromosome.
 - 10. (Twice Amended) A host cell transformed with the recombinant expression vector of claim 6.

34

11. (Twice Amended) A host cell transformed with the nucleic acid molecule of claim

4.

Please cancel claim 12, without prejudice.

- 29. (Amended) An isolated polynucleotide comprising SEQ ID NO:1.
- 30. (Amended) An isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide fragment consisting of amino acid residues 1 to 95 of SEQ ID NO:5.

B5

31. (Amended) An isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide fragment consisting of amino acid residues 1 to 135 of SEQ ID NO:5.

Please cancel claim 35, without prejudice.

REMARKS

The specification has been amended to replace the Sequence Listing with the substitute Sequence Listing submitted herewith as Exhibit A. The substitute Sequence Listing is presented in accordance with a teleconference conducted between Tim Tracy of our firm and the prior Examiner (Examiner Stole) on June 23, 1999.